Metastatic adrenocortical carcinoma treated with sunitinib: A case report

Jeong Ok Lee, Keun Wook Lee, Chung Jong Kim, Yu Jung Kim, Hee Eun Lee, Haeryoung Kim, Jee Hyun Kim, Soo Mee Bang, Jae Sung Kim, Jong Seok Lee

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis. Palliative chemotherapy can be considered in patients with metastatic disease. Although mitotane- or cisplatin-based chemotherapy regimens are widely used, the effects of these agents have been limited. We have experienced a case that showed a partial response with sunitinib after failure of mitotane-based cytotoxic chemotherapy. The clinical benefit from sunitinib persisted 7.5 months in this case. To our knowledge, this is the first reported case showing the effects of sunitinib on metastatic ACC.

Original languageEnglish
Pages (from-to)183-185
Number of pages3
JournalJapanese Journal of Clinical Oncology
Issue number3
StatePublished - 2009


  • Adrenocortical carcinoma
  • Chemotherapy
  • Sunitinib


Dive into the research topics of 'Metastatic adrenocortical carcinoma treated with sunitinib: A case report'. Together they form a unique fingerprint.

Cite this